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Abstract.  The K-FGF/HST (FGF-4) growth factor is 
a member of the FGF family which is efficiently se- 
creted and contains a  single N-linked glycosylation 
signal.  To study the role of glycosylation in the secre- 
tion of K-FGF, we mutated the human K-fgf cDNA to 
eliminate the glycosylation signal and the mutated 
cDNA was cloned into a mammalian  expression vec- 
tor.  Studies of immunoprecipitation  from the condi- 
tioned medium of cells expressing this plasmid re- 
vealed that the lack of glycosylation did not impair 
secretion, however the unglycosylated protein was im- 
mediately cleaved into two NH2-terminally truncated 
peptides of 13 and  15 kD, which appeared to be more 
biologically active than the wild-type protein.  These 
two proteins also showed higher heparin binding affin- 
ity than that of wt K-FGE We have expressed in bac- 
teria the larger of these two proteins (K140),  in which 
the NH2-terminal 36 amino acids present in the mature 
form of K-FGF have been deleted.  Mitogenicity assays 
on several cell lines showed that purified recombinant 
K140 had approximately five times higher biological 
activity than wild-type recombinant K-FGF.  Studies of 
receptor binding showed that K140 had higher affinity 
than wt K-FGF for two of the four members of FGF 
receptor's family, specifically for FGFR-1 (fig) and 
FGFR-2 (bek).  K140 also had increased heparin bind- 
ing ability, but this property does not appear to be re- 
sponsible for the increased affinity for FGF receptors. 
Thus removal of the NH2-terminal 36 amino acids 
from the mature K-FGF produces growth factor mole- 
cules with an altered conformation, resulting in higher 
heparin affinity,  and more efficient binding to FGF re- 
ceptors. Although it is not clear whether cleavage of 
K-FGF to generate K140 occurs in vivo, this could 
represent a novel mechanism of modulation of growth 
factor activity. 
T 
HB K-fgf/hst oncogene (Delli-Bovi et al., 1987; Taira 
et ai., 1987) encodes a heparin-binding protein (FGF-4) 
of the FGF family, whose members share a varying de- 
gree of homology at the amino acid sequence,  and are mito- 
genic for a variety of cell types of epithelial,  mesodermal, 
and neuroectodermal origin.  They can also stimulate neurite 
outgrowth and  inhibit  the differentiation  of myoblasts.  In 
vivo FGFs accelerate wound repair,  stimulate angiogenesis, 
and  can  induce  the  formation  of mesoderm  in  Xenopus 
oocytes (for review  see Basilico and Moscatelli,  1992). 
The response of cells to FGF is mediated through binding 
of two types of cell surface receptors. High affinity receptors 
are tyrosine kinases and include the fig receptor or FGFR-1 
(Lee et al., 1989; Dionne et al., 1990), the bek receptor or 
FGFR-2 (Kornbluth et al., 1988; Dionne et al., 1990; Man- 
sukhani  et al.,  1992),  FGFR-3 (Keegan et al.,  1991), and 
FGFR-4 (Partanen  et al., 1991), while low affinity receptors 
comprise a heterogeneous population of heparan sulfate pro- 
teoglycans (HSPG) t (Moscatelli,  1987). Although it is clear 
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that all or most FGF have to interact with HSPG or heparin 
to bind and activate the tyrosine kinase receptors (Yayon et 
al., 1991; Klagsbrun  and Baird,  1991), little is known about 
the FGF domains that are important for HSPG binding  and 
receptor specificity. 
The human K-fgfcDNA encodes a 206-amino acid poly- 
peptide which contains an NHz-terminal hydrophobic leader 
sequence and a  single  N-linked  glycosylation  signal.  The 
mature protein is efficiently secreted as a glycosylated 22-kD 
polypeptide (Delli-Bovi et al., 1988). N-linked glycosylation 
has been shown to play a role in protein transport to the cell 
surface, and it is known that suppression  of glycosylation by 
site-directed mutagenesis or tunicamycin treatment may lead 
to reduced levels of secretion (Guan et al., 1985; Dorner et 
al.,  1987). 
To study the role of glycosylation in the secretion of K-FGF, 
we eliminated the N-linked glycosylation signal in the K-FGF 
protein by site-directed  mutagenesis of K-fgf cDNA. Cells 
transfected with a plasmid encoding the unglycosylated (glyc-) 
K-FGF appeared to secrete the growth factor in the medium, 
indicating that lack of glycosylation does not impair K-FGF 
secretion.  The absence of glycosylation  however  leads to 
cleavage of K-FGF at the cell surface or immediately  prior 
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peptides of ,x,15 and  13 kD.  These proteins exhibit higher 
affinity for heparin than mature K-FGE Bacterial expression 
of a recombinant K-FGF form corresponding to the 15-kD 
polypeptide (K140) reveals that this protein has higher mito- 
genic activity than wt K-FGF and an increased affinity  for 
at least two of the FGF tyrosine kinase receptors. 
Materials and Methods 
Construction of  a Plasmid Expressing 
Unglycosylated  K-FGF 
A 595-bp EcoRI-SacI fragment, corresponding to the 5' half of the K-fgf 
eDNA, (Delli Bovi et al., 1987) was cloned into the M13mp18 vector. Prep- 
aration of the single-stranded template and site-directed mutngenesis were 
performed as described by Kunkel et al. (1987).  A 25-nucleotide (nt) oligo- 
nucleotide complementary to nt 341 to 366 of  the K-fgfcDNA and carrying 
a T--,C substitution in position 354 to change the threonine codon to alanine 
was used as a primer. DNA from single plaques was purified and sequenced 
by the dideoxynucleotide method (Sanger et al.,  1977).  Double-stranded 
DNA was extracted from a clone carrying the desired mutation. The insert 
was purified after digestion with Sacl, and cloned into the SacI site of a 
pGEM3 derivative that carries the 3' SacI-EcoRI fragment of the human 
K-fgfcDNA, to reconstruct the full length eDNA. The 1.1-kb EcoRI frag- 
ment was then cloned in the EcoRI site of the 91023B  expression vector 
(Wong et al.,  1985). 
Cell Culture and Transfection 
Mouse  NIH3T3  and  monkey  COS-'/  cells  were  grown  in  DME  sup- 
plemented with 10% calf serum. CHO-DG44 cells, which are dihydrofolate 
reductase-negative (DHFR-),  were maintained in DME containing 10% 
FCS, 0.1  mM hypoxanthine, 0.02  mM thymidine, and  10 mM proline. 
CHO-4-1 clone (Mansukhani et al., 1990) and CHO 3.7-5 clone (Mansuk- 
hani et al., 1992) were grown in medium lacking hypoxanthine and thymi- 
dine. 32D bek clone B3 cells (Mansukhani et al., 1992) were maintained 
in Iscove's medium with 10 % heat-inactivated FCS, interleukin-3 (10 U/ml) 
and geneticin (400 #g/ml). COS-7 cells were transfected by the DEAE- 
dextran chloroquine procedure (Luthman and Magnusson 1983) using 3 #g 
of plasmid per 100-ram dish. 
Immunoprecipitation 
COS-7 cells were labeled for 8 h with 200 #Ci/ml of [3S$]methionine  and 
then lysed in RIPA buffer (Delli-Bovi et al., 1988).  The cell lysate was cen- 
trifuged at 12,500 rpm for 30 rain at 4°C. The medium was mixed with 1/4 
vol of 5 x  RIPA buffer.  Cell lysate and media were immunoprecipitated 
overnight at 4"C with rabbit anti-K-FGF antiserum. Immunoprecipitates 
were washed with RIPA buffer and analyzed on a  12%  SDS-PAGE. After 
electrophoresis, the dried gels were fluorographed at  -80°C. 
Induction of Transformed Morphology by K-FGF 
NIH3T3  cells were seeded at  3x  104/well  in DME  supplemented with 
10% calf serum. The next day the cells were washed and starved in DME 
with 0.5% calf serum. 24 h later different  concentrations of  the supernatants 
from COS-7 cells, containing the secreted growth factors, were added. 
12 h later the cells were analyzed for their transformed phenotype. 
Sequencing the NH2 Terminus  of the Truncated 
K-FGF Forms 
Tritiated leucine-labeled proteins from the medium of COS-7 cells trans- 
fected with  the plasmid expressing the glyc- K-FGF were purified by 
precipitation with a pelyclonal antibody raised against full length K-FGE 
The amino terminus of the purified proteins was sequenced using a protein 
sequencer (model 470A; Applied Biosystems, Foster City, CA) with the an- 
tibody acting as a carrier protein. The samples from each round of Edman 
degradation were tested for radioactivity and tritium was found in several 
cycles allowing them to be assigned as ieucine residues in the K-FGF se- 
quence. There was a major sequence and a minor sequence. In both cases 
there was only one possible start site that would generate the Leucine resi- 
due pattern identified by the sequencer. The major sequence started at resi- 
due 67 of the K-FGF full length sequence and the minor at residue 110. 
Expression and Purification of  Recombinant K140 
The full length eDNA for K-FGF was mutated using site-directed mutagen- 
esis to remove the nucleotides coding for the first 66 amino acids and re- 
place them with the sequence for a methionine codon. For high level expres- 
sion, it was found necessary to change the codon usage pattern of the first 
seven amino acids to decrease the GC bias of the sequence. The now se- 
quence reads 5'-ATG GCA GCA GTT CAA TCA GGA GCA -3' and does 
not change the amino acid sequence of the protein. This mutated sequence 
was inserted into a vector PA/L-781  which allowed expression under the 
control of the pL promoter and the cII ribosome binding site (Shimatake 
and Rosenberg 1981). The GI-595 Escherichia  coli strain used to express 
K-FGF had a temperature sensitive lambda repressor. After growth at the 
permissive temperature, the temperature of the culture was raised allowing 
expression of K140. Cells were broken in a Gaulin homogenizer and the in- 
soluble K140 was extracted using a high salt buffer (0.75 M NaCI, 50 mM 
Hepes, pH 7.5),  and purified by Heparin/Toyopearl column chromatogra- 
phy. Protein concentration of recombinant growth factor preparations was 
measured spectrophotometrically by its absorbance at 280 nm and by the 
Bradford procedure  (Bio  Rad  Labs.  Hercules,  CA).  Both  assays were 
calibrated using K-FGF protein, whose concentration had been determined 
by amino acid composition analysis. 
Mitogenic Assays 
BALBc/3T3  cells were plated at 3x104 cells/well in 24-well plates in DME 
supplemented with 10%  calf serum. The cells were starved in 0.5% calf 
serum and after 48 h serial dilutions of recombinant growth factors were 
added.  18  h  later  the  cells  were  labeled  with  1  #Ci/ml  of  [methyl- 
3H]thymidine for 6 h, washed with PB$ and the incorporation into acid- 
precipitable material was determined. Each assay was performed in trip- 
licate. 
32D  cells  at  2.5x104  cells/well,  were  seeded  in  96-well  plates  in 
Iscove's medium in the presence of 10% heat-inactivated FCS and different 
concentrations of heparin and growth factors. After 18 h the cells were la- 
beled with [methyl-3H]thymidine and the incorporated radioactivity was 
determined as described above. 
Radioiodination and Binding of  FGFs 
Human recombinant bFGF (specific activity 5 x 104 cpm/ng) was radioiodi- 
hated using the mild chloramine-T method (McConahey and Dixon, 1980) 
and purified over a Sephadex G-25 column in the presence of 1% of BSA. 
Recombinant K-FGF (specific activity 9x103 cpm/ng) and Kl40 (specific 
activity 1.5 xl04 cpm/ng) were iodinated with l~I-labeled Bolton-Hunter 
reagent for 4 h on ice and purified on Sephadex G-25 colunm using as buffer 
PBS/2 M NaCl/0.25 % gelatin. For competition binding assays, CHO cells 
were plated at lxl06 cells/35-mm dish and analysis was performed as de- 
scribed (Mansukhani et al.,  1990).  For Scatchard analysis cells were in- 
cubated at 4°C with DME containing 0.15 % gelatin, 25 mM Hepes, pH 7.4, 
heparin (10/zg/ml), and various concentration of 125I-labeled K-FGF or 
K140. After 2 h the medium was removed, the cells were washed with ice- 
cold  TRIS  and  the  radioactivity  bound to  high  affinity  receptors was 
released and extracted in 0.6%  SDS, 50 mM TRIS/HCI pH 7.4, 0.15 mM 
NaC1, 5 mM EDTA. Nonspecific binding was determined using the same 
amount of growth factor on parental CHO DG-44 cells that do not express 
FGF receptors. 
Results 
Effect of the Lack of Glycosylation on 
K-FGF Processing 
The human K-FGF precursor protein is a 206-amino acid 
polypeptide with a hydrophobic leader sequence and an Asn- 
Gly-Thr consensus sequence for N-linked glycosylation (Fig. 
1). Processing of the immature form in the ER cleaves the 
signal  peptide  at  residues  30  or  31,  and  the  protein  is 
glycosylated and secreted in the culture medium as a mature 
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To study the role of glycosylation on secretion of K-FGF, we 
eliminated the  N-linked  glycosylation signal  sequence by 
substitution of threonine 38 with alanine, using oligonucleo- 
tide-directed mutagenesis (Fig.  1). The modified glyc- eDNA 
was cloned into the 9102303) mammalian expression vector, 
which contains the adenovirus major late promoter and the 
SV-40 replication origin (Wong et al., 1985), and the plasmid 
was introduced into simian COS cells, that constitutively ex- 
press SV-40 large T antigen. 48 h later the conditioned me- 
dium from COS cells transfected with the glyc- mutant was 
tested for its ability to induce transformed morphology or 
DNA synthesis in serum starved NIH3T3 cells. This activity 
was found comparable with or even higher than that of the 
conditioned medium from COS cells transfected with the un- 
modified K-fgfcDNA, indicating that in the absence of gly- 
cosylation the protein is efficiently secreted. Transfection of 
plasmids  expressing the  glyc- K-FGF  into  NIH3T3  cells 
showed that their transforming ability was  comparable to 
that  of plasmids  expressing  wild-type (wt)  K-FGF.  Since 
transformation by K-FGF requires secretion (Talarico and 
Basilico, 1991; Fuller-Pace et al.,  1991), this also indicated 
that  lack of glycosylation did not significantly impair se- 
cretion. 
Surprisingly,  however,  when  the  medium of COS  cells 
transfected with  the plasmid  expressing the  glyc- K-FGF 
was subjected to immunoprecipitation with anti-K-FGF anti- 
bodies, no K-FGF species of 18 kD (the expected molecular 
weight  of unglycosylated,  mature  K-FGF)  was  observed 
(Fig. 2). While this form was easily detected in the cell ly- 
sate,  the conditioned medium only contained two K-FGF 
forms of 15-13 kD, suggesting that the absence of  glycosylation 
had exposed sites sensitive to proteases, active at the cell sur- 
face or just before secretion, leading to immediate cleavage 
of  the protein upon release. To confirm this conclusion, COS 
cells  transfected with  the  wt or  the  glyc- K-fgf plasmids 
were grown in the presence or the absence of tunicamycin, 
an inhibitor of N-linked glycosylation. The cells were la- 
beled with [35S]methionine  and the cell extracts or the cul- 
ture medium were subjected to immunoprecipitation with 
rabbit anti-K-FGF serum. As shown in Fig. 2, in the absence 
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Figure L Amino acid sequence of  the human K-FGF precursor pro- 
tein. The hydrophobic signal peptide is underlined. The arrows in- 
dicate the sites of cleavage of the mature, secreted form of K-FGE 
Asterisks  indicate the glycosylation signal. The mutation  intro- 
duced in the eDNA to eliminate glycosylation is indicated above 
(Thr--*Ala). The brackets indicate the sites of cleavage which gen- 
erates the  15-kD K140 and the  13-kD K97 protein. 
Figure 2. Immunoprecipitation of the K-FGF species produced in 
COS-7 ceils transfected with the glyc- K-fgf eDNA. Autoradiog- 
raphy of an SDS-PAGE (12.5  % acrylamide) of immunoprecipitates 
of the conditioned medium (M) and lysates (L) from [35S]methio- 
nine-labeled COS-7 cells transfected with the glye- K-fgfor the wt 
K-fgf  eDNA plasmids incubated in the presence (+) or absence (-) 
of tunieamycin (10 ~g/ml). The arrows indicated the K-FGF forms 
immunoprecipitated  by  anti-K-FGF  antibodies.  The molecular 
weight markers are indicated on the right. 
of tunicamycin, anti-K-FGF antibodies immunoprecipitated 
a 22-kD protein from K-fgftransfected cells. In K-fgftrans- 
fected cells treated with tunieamycin, an 18-kD protein is de- 
tected in  the cell lysates,  as  in  ceils transfected with the 
glyc-  mutant.  Tunicamycin  causes  a  somewhat  reduced 
secretion, but lower molecular weight K-FGF forms comi- 
grating with those produced by the glyc- eDNA can be de- 
tected in the culture medium. Thus in both cases the absence 
of glycosylation results in extracellular cleavage of K-FGF 
to generate two lower molecular weight forms. Similar re- 
suits were obtained by the analysis of NIH3T3 cells stably 
transfected with the glyc- K-fgf  plasmid (data not shown). 
Heparin Binding Properties of the Truncated 
Forms of  K-FGF 
To determine whether heparin interacted with the truncated 
K-FGF forms and  stabilized them as it does with mature 
K-FGF (Delli Bovi et al., 1988), we tested the effect  of hepa- 
rin on the recovery of these polypeptides from the condi- 
tioned medium of transfected COS cells. Cells were labeled 
for 8 h  with [3~S]methionine  in the presence or in the ab- 
sence of heparin (10 #g/ml, H). Culture medium and cell ly- 
sates were immunoprecipitated and analyzed. In some cases 
(+h) equal aliquots of the medium or lysates collected in the 
absence of heparin were incubated with 10/~g/ml of heparin 
for 1 h before immunoprecipitation (Fig. 3). As previously 
described (Delli Bovi et al.,  1988), the presence of heparin 
in the medium during culture increases the recovery of K-FGE 
although in this experiment the effect of heparin does not ap- 
pear striking because of the labeling conditions. Addition of 
heparin to the culture medium before immunoprecipitation 
had no significant effect. On the other hand, in the case of 
the proteins produced by the glyc- mutant, the amounts of 
the truncated proteins detected in the medium are maximal 
Bellosta et al.  Truncated K-FGF with Higher Biological Activity  707 Figure 3. Heparin affects the recognition by antibodies of the trun- 
cated forms of K-FGF produced by the glye- mutant. COS-7 cells 
transfected with the wt or glyc-K-fgf  eDNA plasmids were labeled 
with [35S]methionine for 8 h in the presence (H) or absence of 
heparin in the culture medium (10 #g/ml). Media and cell lysates 
were immunoprecipitated with anti-K-FGF antibodies. Equal ali- 
quots of the medium or lysate collected in the absence of heparin 
were also incubated with 10 t~g/ml of beparin for 1 h before immu- 
noprecipitation (+h). The immunopreeipitates were run on 12.5 % 
SDS-PAGE followed  by autoradiography. The K-FGF forms are in- 
dicated by arrows on the left. The migration of molecular weight 
standards are indicated on the right. 
in the absence of heparin. When the medium is preincubated 
with heparin before immunoprecipitation (+h),  there is a 
considerable decrease in the amount of recovered proteins 
(Fig. 3). Western analysis showed that the amounts of trun- 
cated proteins present in these media were not affected by the 
addition of heparin after harvesting, and that the presence of 
heparin during culture actually increased somewhat the re- 
covery  of  the truncated K-FGF forms (data not shown). Thus 
these data suggest that the binding of  heparin to the truncated 
K-FGF molecules inhibits or competes for antibody recog- 
nition. 
To investigate further the interaction of heparin with the 
truncated K-FGF species, the conditioned medium labeled 
with [3~S]methionine collected from COS cells transfected 
with either the K-fgf cDNA or the glyc- mutant was  ab- 
sorbed to a heparin-Sepharose column and eluted with in- 
creasing NaCI concentration. Fractions were immunopre- 
cipitated with anti-K-FGF antibodies,  and run on SDS-PAGE. 
It can be seen in Fig. 4 that K-FGF eluted at 1.1 M  NaC1, 
while the 13- and 15-kD proteins eluted with a peak at 1.3- 
1.5 M NaC1, indicating that the affinity for heparin of these 
proteins is higher than that of K-FGE  Thus the truncated 
forms of K-FGF also bind heparin with higher affinity than 
the wild type. 
Expression of a Truncated Form of  K-fgf 
Titration of the mitogenic activity present in the medium of 
cells transfected with the glyc- K-fgf  cDNA, relative to the 
amounts of truncated proteins estimated by Western blot, in- 
Figure 4. Elution of truncated K-FGF forms from heparin affinity 
columns. Conditioned medium labeled with [35S]methionine  pro- 
duced from COS-7 cells transfected with the wt or glye- K-fgf 
cDNA was absorbed to heparin-Sepharose and eluted with the in- 
dicated molar NaCl concentrations. Fractions were immunopre- 
cipitated  with  anti-K-FGF  antibodies and run on  12.5% SDS- 
PAGE. The molecular weights of the K-FGF forms are indicated 
by the arrows. The molecular weight markers are on the fight. 
dicated  that  these  truncated  K-FGF  forms  had  a  higher 
specific activity than that ofwt K-FGE To verify this finding, 
we decided to characterize the cleavage sites to genetically 
engineer recombinant versions of the truncated K-FGF, pu- 
rify the expressed protein to homogeneity and compare its 
properties with that of full length recombinant K-FGE Im- 
munoprecipitation analysis with  antibodies  raised  against 
peptides  that  recognize  the  COOH-terminus  of  K-FGF, 
showed that the two truncated species were deleted in the 
NH2-terminal part of the molecule (data not shown). 
To sequence the two polypeptides of 13 and 15 kD, COS 
cells,  transfected with glyc- K-fg/eDNA,  were metaboli- 
cally labeled with  [3H]leucine.  The labeled proteins were 
purified by immunoprecipitation with anti-K-FGF antibod- 
ies.  The amino terminus of the purified proteins was  se- 
quenced as described in Materials  and Methods.  The se- 
quence of the largest polypeptide was identified as starting 
at residue 67 of the full length K-FGF protein, and that of 
the shorter and less abundant protein at residue 110 (Fig. 1). 
The 140-amino acid polypeptide (K140) has lost most of the 
amino-terminal region unique  to  K-FGF within the  FGF 
family, but retained the central homologous core region. The 
97-amino acid polypeptide has also lost part of the central 
homologous core region and has not been further studied. 
The K-fgf cDNA sequence was altered using site-directed 
mutagenesis to delete the first 66 amino acids and place an 
initiator methionine in front of residue 67. The 140-amino 
acids polypeptide (K140) was cloned in the bacterial expres- 
sion vector PA/L-781  under the control of the pL promoter 
and the cII ribosome binding site and expressed in E. coli. 
To increase the amount of K140 produced by the bacteria, 
the cDNA was modified, to reduce its GC content, without 
changing the amino acid sequence of the protein (see Mate- 
rials and Methods). The protein was purified and its biologi- 
cal activity compared with that of recombinant K-FGF. As 
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produced,  full length K-FGF (data not shown). 
Mitogenic Activity of the KI40 Protein 
To  study  the  biological  activity of the  recombinant K140 
molecule, its ability to stimulate cell proliferation was com- 
6000 
pared with that of recombinant K-FGF using a DNA synthe- 
sis assay on several fibroblast and endothelial cell lines. Cells 
were incubated for 2 d in medium containing 0.5 % serum, 
and then treated with different concentration of K-FGF or 
K140.  18 h later the cells were labeled with [3H]thymidine 
for 6 h and the effects on DNA synthesis were calculated by 
measuring the incorporation of radioactivity into acid-insolu- 
ble material. A representative experiment using the BALB/c 
3T3 cell line is shown in Fig. 5. As can be seen, K140 was 
about five times more efficient than K-FGF in inducing DNA 
synthesis. At low doses, about five times more K-FGF than 
K140 is required to achieve the same stimulation of DNA 
synthesis, and maximal stimulation was observed at 1 ng/ml 
with K140 and 5  ng/ml with K-FGE  Similar results were 
obtained using NIH 3T3 cells and human umbilical vein en- 
dothelial cells (data not shown).  Surprisingly, the stimula- 
tion of DNA synthesis obtained with K140 was always some- 
what higher than that produced by K-FGF, even at growth 
factor concentrations producing maximal stimulation. This 
small but reproducible difference could be due to the fact that 
K140 can recruit into DNA synthesis cells that are not in- 
duced by K-FGE perhaps because they express a low num- 
ber of receptors. 
The lower mitogenic activity of K-FGF with respect to 
K140 does not appear to be the result of higher susceptibility 
of the former to proteolytic digestion by factors present in 
the conditioned  medium.  Western blotting analysis, using 
anti-K-FGF antibodies,  showed that incubation of K-FGF 
and K140 in the conditioned medium of NIH 3T3 at 37°C 
for 24 h  did not induce significant proteolytic degradation 
(data not shown). It is worth mentioning here that the biolog- 
ical activity of K140 can be neutralized as well as that of 
K-FGF by neutralizing  antibodies raised in rabbits against 
the mature recombinant K-FGF protein. 
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Figure 5. Mitogenic activity in quiescent BALB/c-3T3 cells by hu- 
man recombinant  K-FGF or by recombinant  K140. BALB/c-3T3 
ceils were incubated for 2 d in medium containing 0.5%  serum, 
cells were treated with the indicated concentration of K140 (m) or 
K-FGF ([]).  18 h later the cells were labeled with [3H]thymidine 
for  6 h and radioactivity incorporated into cellular DNA was counted 
after TCA precipitation.  Stimulation by 10%  serum (@). 
FGF  (nglml) 
Figure 6. Competitionbinding  of bFGF, K-FGF, and K140 to CHO cells expressing FGFR-1 or CHO cells expressing FGFR-2. CHO cells 
were incubated at 4°C with nSI-labeled bFGF (4 ng/ml) and the indicated concentrations  of unlabeled bFGF (zx), K-FGF (R), or K140 
(e), in the presence of heparin (10 #g/ml) as described in Materials and Methods. After 2 h the cells were washed with 2 M NaCI buffered 
at pH 7.4 to remove the growth factor bound to low affinity receptors,  and with 2 M NaCI buffered at pH 4.0 to remove the ligand bound 
to high affinity receptors.  The amount of I25I-labeled  bFGF bound to high affinity receptors  was determined. 
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Figure 7. Competition assay for binding of 125I-K140 and 125I-K-FGF  by K-FGF and K140. CHO clones expressing FGFR-1 (.4 and C) 
or CHO clones expressing FGFR-2 (B and D) were incubated with t25I-labeled K140 (6 ng/ml) (A and B) or with nSI-labeled K-FGF (5 
ng/ml) (C and D), and the indicated concentrations  of unlabeled K140 (m) or K-FGF (D) in the presence of heparin (10 #g/ml) as de- 
scribed in Materials and Methods. After 2 h at 4°C the medium was removed and the cells were washed with ice cold TRIS and lysed 
in 0.6% SDS/50 mM TRIS/HC1 pH 7.4, 0.15 M NaC1, 5 mM EDTA. The cell associated radioactivity was determined.  The data are ex- 
pressed as percent of inhibition of labeled growth-factor binding by the indicated amount of unlabeled growth factor. 
Receptor Binding Analysis on CHO Cells Expressing 
FGFR-1 and FGFR-2 
The higher mitogenic activity of K140 could have been re- 
lated to a higher affinity for FGF receptors. Since 3T3 cells 
express multiple species of FGF receptors (Partanen et al., 
1991,  our own unpublished  results),  and that would have 
complicated the analysis, we performed ligand binding anal- 
ysis on CHO cells expressing the murine FGFR-1 (fig) (Man- 
sukhani et al.,  1990) or FGFR-2 Cock) receptors (Mansuk- 
hani  et al.,  1992).  In the  first  series  of experiments,  we 
performed competition experiments for binding to FGFR-1 
or -2, using iodinated bFGF as the ligand (Fig. 6). As previ- 
ously described, bFGF binds FGFR-1 with "~10 times higher 
affinity than K-FGF, while both growth factors bind FGFR-2 
with the same high affinity (Mansukhani et al., 1990; 1992). 
The K140 protein competes for bFGF binding to FGFR-1 as 
effectively as bFGF itself, and significantly more efficiently 
than  wild-type K-FGF.  Binding  to  FGFR-2  is  also  more 
efficient with about two or three times higher affinity than 
that of bFGF and K-FGE 
To confirm this conclusion, CHO cells expressing the fig 
or bek receptor were incubated with iodinated K-FGF or 
K140,  and binding was competed with various concentra- 
tions of unlabeled ligands (Fig. 7). In all cases, and irrespec- 
tive of whether the labeled ligand was K-FGF or K140, about 
five times more K-FGF than K140 was required to compete 
for binding to receptor 1, while in the case of receptor 2 the 
affinity of K140 was about twice that of K-FGF. To confirm 
that K140 has higher affinity than K-FGF for FGFR-1 and 
FGFR-2, the relative dissociation constants were determined 
by saturation binding analysis. As shown in Fig. 8 Scatchard 
analysis for FGFR-1 gave a straight line, indicating a single 
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Figure  8. Scatchard analysis of 
K-FGF and K140 binding to 
CHO ceils expressing  FGFR-I. 
Ceils at 4.8 x  l@/35-mm dish 
were  incubated  at  4°C  with 
DME containing 0.15% gela- 
tin,  25  mM Hepes,  pH 7.4, 
heparin (10/zg/ml) and concen- 
trations  of ~25I-labeled K140 
(m) or K-FGF (o) ranging from 
0.15 to 20 ng/ml. After 2 h the 
medium was removed, and the 
radioactivity bound to the high 
affinity receptors  was  deter- 
mined as described in Mate- 
rials and Methods. 
class of binding sites. From these data the Kd for FGFR-1 is 
~90 pM for K140 and 280 pM for K-FGF. Similar results 
were obtained for cells expressing FGFR-2, where the K~ 
was '~60 pM for K140 and 140 pM for K-FGF (not shown). 
We also measured binding of K140 and K-FGF to cells ex- 
pressing  FGFR-4.  This receptor has been shown to have 
maximal affinity for aFGF, with bFGF and K-FGF binding 
about ten times less efficiently (Vainikka et al., 1992). KI40 
did not appear to bind FGFR-4 more efficiently than K-FGF 
(data not shown),  suggesting that the increased affinity of 
K140 for FGFR-1 and 2 is receptor-specific. 
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Figure 9.  Stimulation of DNA synthesis in 32D bek B3 cells by 
K-FGF or K140. Cells were incubated in Iscove's medium contain- 
ing 10% FCS and different concentrations of  heparin. 18 h after ad- 
dition of the growth factor, the cells were labeled with [3H]thymi- 
dine for 6 h and radioactivity incorporated was determined after 
TCA precipitation. A represents data obtained using 10 ng/ml of 
K-FGF (o) or K140 (¢), B using 0.3 ng/ml of the growth factors. 
In the absence of growth factors, the amount of radioactivity incor- 
porated was the same as that obtained in the absence of heparin. 
DNA Synthesis in Transfected 32D Cell Expressing 
FGF Receptors 
FGFs require an interaction with heparin or HSPGs to be 
capable of  binding and activating their tyrosine kinase recep- 
tors (Yayon et al., 1991). It was therefore conceivable that the 
higher affinity of the K140 protein for two of the FGF recep- 
tors could have been due, at least in part, to its higher affinity 
for heparin with respect to K-FGE To test this hypothesis, 
we measured the mitogenic effect of K140 and K-FGF on 
32D cells expressing the bek receptor. 32D cells are IL-3 de- 
pendent murine hematopoietic cells, that do not express de- 
tectable levels of HSPGs or high affinity FGF receptors. 
When these cells are transfected to express FGF receptors, 
they can be induced to proliferate by FGFs, but this response 
requires the presence of heparin in the culture medium (Man- 
sukhani et al., 1992). 32D ceils expressing the bek receptor 
were seeded at 25,000 ceUs/weU in 96-well plates in  10% 
FCS and different concentrations of growth factors or heparin 
were added.  After  18 h  the ceils were labeled with [3H]- 
thymidine and the effects on DNA synthesis were calculated 
by measuring the incorporation of radioactivity into acid in- 
soluble material (Fig. 9). The data show that in the absence 
of  heparin both K140 or K-FGF failed to stimulate DNA syn- 
thesis.  At  high  growth  factor concentrations  (10  ng/ml), 
K140 does not appear to exhibit lower heparin requirements 
than K-FGF, as both factors begin to be mitogenic at a con- 
centration of heparin of •50  ng/ml and produce maximal 
stimulation in the presence of ,x,1 ~tg/ml of heparin (Fig. 
9 A).  At low concentrations of growth factor (0.3 ng/ml), 
K-FGF appears to be slightly more heparin dependent for its 
mitogenic activity than K140, but this difference is not strik- 
ing (Fig.  9  B).  We interpret these data as indicating that 
binding of K140 to its receptors also requires heparin (and 
this was also confirmed by direct binding experiments, not 
shown), but that the higher mitogenic and receptor binding 
activity of K140 with respect to wild-type K-FGF cannot be 
simply explained by its higher affinity for heparin, although 
this property could be a contributing factor. Similar results 
were obtained with 32D cells expressing the fig (FGFR-1) 
receptor. 
Discussion 
The studies presented in this manuscript were initiated to de- 
termine precisely whether glycosylation of the K-FGF mole- 
cule,  a  growth factor of the FGF family that is normally 
efficiently secreted, was important for processing and secre- 
tion.  We thus  eliminated the  unique  glycosylation signal 
which is present in the K-FGF molecule near its NH2 ter- 
minus by site-directed mutagenesis of  the human K-fgfcDNA. 
Expression of this mutated form of K-FGF in mammalian 
COS and NIH3T3 cells showed that the absence of glycosyla- 
tion does not impair processing and secretion of K-FGE The 
cleaved, mature form of unglycosylated K-FGF is however 
only  detected  intracellularly.  All  extracellular  K-FGF  is 
shortened by cleavage at residues 66 or 109 to generate two 
NH2-terminally truncated molecules. 
Cleavage must predominantly occur during the external- 
ization process or at the cell surface, as we were never able 
to detect any full length unglycosylated protein in the culture 
medium. The nature of  the proteases involved in the cleavage 
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tease cleavage site at amino acid 66, and thus these proteases 
could be similar. Thus, the absence of glycosylation  leads to 
exposure of protease sensitive sites that are normally pro- 
tected in the K-FGF molecule. These sites are not immedi- 
ately located within the region of attachment of the sugar 
chains, but are distal to it. It appears therefore that the ex- 
posure of these protease-sensitive sites results from changes 
in the structure or folding of the K-FGF molecule, resulting 
in the uncovering of sites which are normally protected by 
steric interference of sugar residues or by the folding of the 
molecule. 
The unexpected result of this proteolytic cleavage  is the 
generation of two lower molecular weight K-FGF species 
which have a higher affinity for heparin and of which one at 
least, has higher biological activity. These findings suggest 
that the truncated K-FGF forms must undergo some changes 
in tertiary structure, which differentiate them from mature 
K-FGE It is particularly worth mentioning here that they do 
not only exhibit higher affinity for heparin, but that heparin 
appears to bind these molecules in a different way from that 
of mature K-FGE In fact, while heparin binding does not 
generally affect K-FGF recognition by antibodies, the bind- 
ing of heparin to the truncated molecules appears to inhibit 
antibody recognition (Fig. 3), and this effect is particularly 
evident with antipeptide sera raised against the COOH ter- 
minus of the protein (data not shown). This finding suggests 
that heparin binding is not only a function of primary amino 
acid sequence but is also influenced by the configuration of 
the protein molecule, although alternative explanations can- 
not be ruled out. It is interesting to note that an earlier study 
(Burgess  et al.,  1985) had suggested that a truncated form 
of acidic FGF had increased heparin affinity. 
Another finding supporting the hypothesis that these trun- 
cated molecules must assume a novel spacial configuration 
is that fact that the longest of them, K140, has higher mito- 
genic activity than that of wild-type K-FGE This higher bio- 
logical activity seems to result, for the most part, from the 
increased affinity for two of the FGF receptors, fig and bek, 
which are the most widely expressed members of this recep- 
tor family. It is not immediately apparent why a truncated 
form of this growth factor would have higher receptor bind- 
ing.  The higher affinity for heparin,  with its consequent 
faster "activation" of the growth factor to a receptor binding 
form does not seem to be responsible (although it may con- 
tribute to its higher biological activity), as our binding ex- 
periments were performed using growth factor concentra- 
tions (2--4 ng/ml) at which we cannot detect any differential 
effect of heparin on K140 with respect to K-FGF (not shown). 
It cannot be excluded however that binding of K140 to hepa- 
rin results in conformational changes which are more favora- 
ble to receptor binding than those undergone by full length 
K-FGF. It has been suggested that heparin facilitates FGF di- 
merization, a property that may be important for receptor 
activation (Ornitz et al., 1992). It is possible that the interac- 
tion of K140 with heparin or HSPG leads to the formation 
of dimers that are more stable than those formed by K-FGE 
Analysis of the crystal structure of basic and acidic FGF 
shows that the NH2-terminal region of these molecules is in 
a flexible and disordered configuration, and does not con- 
tribute to the folding of the rest of the molecule (Eriksson 
et al.,  1991; Zhang et al.,  1991; Zhu et al.,  1991). If the 
K-FGF crystal structure is analogous, it could be speculated 
that removal of its NH2-terminal region leads to the forma- 
tion of a molecule which is more "compact" and organized, 
and thus could form a more stable association with the ligand 
binding domain(s) of the receptor. It is likely however that 
the explanation of this phenomenon is more complex,  as 
K140 does not bind more efficiently  than wt K-FGF to a third 
FGF receptor,  FGFR-4.  Thus a  component of specificity 
must be involved in the increased receptor binding of K140. 
The answer to these questions will probably have to wait for 
the elucidation of the crystal structure of the K-FGF and 
K140 molecules. 
The expression of wild-type K-FGF by both COS and CHO 
cells generates a low level of a truncated form of growth fac- 
tor, suggesting that cleavage of glycosylated K-FGF can oc- 
cur (our own unpublished results). The fact that the response 
of target cells in vitro is altered in both the maximum re- 
sponse (cells recruited) and sensitivity, hints at the intriguing 
possibility that truncated K-FGF has a specific function in 
vivo.  The cellular location, distribution, and regulation of 
the proteases that cleave K-FGF are unknown but may play 
a role in producing novel forms of K-FGE Currently few tis- 
sues have been shown to express K-FGF and those that do, 
do so during early stages of development (Niswander and 
Martin,  1992) making the natural synthesis of this growth 
factor difficult to characterize. An understanding of the bio- 
logical role of K140 will require further study. 
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